Triple negative breast cancer (TNBC) with absent expression of estrogen receptor, progesterone receptor and HER2/neu, accounting for 15-20% of all breast cancer cases and characterized by biological heterogeneity, has the least favorable prognosis [3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.